NDA 022465 · Novartis
Votrient
Pazopanib Hydrochloride · Oral
NovelOrphanLast checked: Nov 20, 2026Latest source record: Jan 25, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Oct 19, 2009
Approved uses
4
Original approval plus efficacy supplements
Registered trials
272
22 Phase 3, 12 recruiting
FAERS reports
22,529
13,736 serious, 6,020 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: HEPATOTOXICITY Severe and fatal hepatotoxicity has been observed in clinical trials. Monitor hepatic function and interrupt, reduce, or discontinue dosing as recommended [see Warnings and Precautions (5.1)]. WARNING: HEPATOTOXICITY See full prescribing information for complete boxed warning. Severe and fatal hepatotoxicity has been observed in clinical trials. Monitor hepatic function and interrupt, reduce, or discontinue dosing as recommended. ( 5.1 )
What it is approved for
From the label in effect Dec 16, 2025.
VOTRIENT is a kinase inhibitor indicated for the treatment of adults with: advanced renal cell carcinoma (RCC). ( 1.1 ) advanced soft tissue sarcoma (STS) who have received prior chemotherapy. ( 1.2 ) Limitations of Use : The efficacy of VOTRIENT for the treatment of patients with adipocytic soft tissue sarcoma or gastrointestinal stromal tumors has not been demonstrated. 1.1 Renal Cell Carcinoma VOTRIENT ® is indicated for the treatment of adults with advanced renal cell carcinoma (RCC). 1.2 Soft Tissue Sarcoma VOTRIENT is indicated for the treatment of adults with advanced soft tissue sarcoma (STS) who have received prior chemotherapy. Limitations of Use : The efficacy of VOTRIENT for the treatment of patients with adipocytic STS or gastrointestinal stromal tumors has not been demonstrated.
Mechanism: Pazopanib is a multi-tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR)-α and -β, fibroblast growth factor receptor (FGFR)-1 and -3, cytokine receptor (Kit), interleukin-2 receptor-inducible T-cell kinase (Itk), lymphocyte-specific protein tyrosine kinase (Lck), and transmembrane glycoprotein receptor tyrosine kinase (c-Fms). In vitro, pazopanib inhibited ligand-induced autophosphorylation of VEGFR-2, Kit, and PDGFR-β receptors. In vivo, pazopanib inhibited VEGF-induced VEGFR-2 phosphorylation...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 18, 2014 Supplement 19 · Efficacy LetterLabel
- Apr 26, 2012 Supplement 10 · Efficacy LetterLabel
- Jan 12, 2012 Supplement 7 · Efficacy LabelLetter
- Oct 19, 2009 Original approval · Type 1 - New Molecular Entity NovelLetterLabelReview
2 products under this application
- VOTRIENT · PAZOPANIB HYDROCHLORIDE EQ 200MG BASE · TABLET, ORAL · Prescription · TE AB
- VOTRIENT · PAZOPANIB HYDROCHLORIDE EQ 400MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Pazopanib" as an intervention, any sponsor and status, largest first.
- A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01235962 · 1,538 participants · Start Nov 30, 2010 · Primary completion Oct 15, 2015
Drug: pazopanib; placebo and 2 more · For: Renal Cell Carcinoma (RCC); Cancer
Sites: Jonesboro, Arkansas; Antioch, California; Beverly Hills, California · 312 sites in all
- Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell CarcinomaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00720941 · 1,110 participants · Start Aug 14, 2008 · Primary completion May 21, 2012
Drug: Pazopanib; Sunitinib · For: Carcinoma, Renal Cell
Sites: Huntsville, Alabama; Tucson, Arizona; Little Rock, Arkansas · 227 sites in all
- Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal CancerPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00866697 · 940 participants · Start May 26, 2009 · Primary completion Jul 8, 2012
Drug: Pazopanib; Placebo · For: Ovarian Cancer
Sites: Anaheim, California; Baldwin Park, California; Bellflower, California · 318 sites in all
- Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatmentPivotal-lookingRecruiting
Centre Leon BerardAcademic, hospital or other
NCT02029001 · 900 participants (planned) · Start Mar 2014 · Primary completion Jan 2028
Drug: Nilotinib (400 mg BID); Everolimus (10 mg QD) and 4 more · For: Malignant Solid Neoplasms
Sites: Bordeaux, France; Lyon, France; Marseille, France · 7 sites in all
Technical University of MunichAcademic, hospital or other
NCT01613846 · 544 participants (planned) · Start May 2012 · Primary completion Oct 30, 2016
Drug: Sorafenib+Pazopanib; Pazopanib+Sorafenib · For: Renal Cell Carcinoma
Sites: Innsbruck, Austria; Kufstein, Austria; Linz, Austria · 72 sites in all
- Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular DegenerationPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01134055 · 510 participants · Start Jun 1, 2010 · Primary completion Oct 1, 2012
Drug: pazopanib eye drops; placebo and 1 more · For: Macular Degeneration
Sites: Peoria, Arizona; Phoenix, Arizona; Tucson, Arizona · 77 sites in all
- Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell CarcinomaStatus unknown
RenJi HospitalAcademic, hospital or other
NCT05816642 · 500 participants (planned) · Start Aug 1, 2022 · Primary completion Dec 31, 2023
Drug: sunitinib or pazopanib; PD-1 inhibitor combined with axitinib · For: Metastatic Renal Cell Carcinoma
Sites: Shanghai, China
- Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell CarcinomaPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00334282 · 435 participants · Start Apr 2006 · Primary completion May 2008
Drug: Pazopanib; placebo · For: Carcinoma, Renal Cell
Sites: Capital Federal, Argentina; Córdoba, Argentina; Rosario, Argentina · 99 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death4,278
- diarrhoea3,309
- fatigue2,226
- nausea2,199
- decreased appetite1,272
- vomiting1,228
- drug ineffective1,227
- malignant neoplasm progression1,168
- hypertension1,080
- malaise822
- weight decreased815
- asthenia804
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2009 | 1 |
| 2010 | 212 |
| 2011 | 694 |
| 2012 | 968 |
| 2013 | 1,676 |
| 2014 | 2,372 |
| 2015 | 3,187 |
| 2016 | 2,244 |
| 2017 | 2,435 |
| 2018 | 2,329 |
| 2019 | 2,003 |
| 2020 | 1,398 |
| 2021 | 1,136 |
| 2022 | 850 |
| 2023 | 615 |
| 2024 | 198 |
| 2025 | 113 |
| 2026 | 98 |
Recalls
1 FDA enforcement reports for this application.
Nov 20, 2023 · Class III · Completed
Failed Dissolution Specifications
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Votrient (Pazopanib HCl)
2024 spending
$22.2M
Beneficiaries
409
1,939 claims
Per beneficiary
$54,275
$135.89 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $147,821,583 |
| 2021 | $126,114,097 |
| 2022 | $106,613,649 |
| 2023 | $97,957,715 |
| 2024 | $22,198,389 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.
van der Graaf WT, Blay JY, Chawla SP, et al. · Lancet 2012 · Clinical Trial, Phase III, Multicenter Study
- First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis.
Aldin A, Besiroglu B, Adams A, et al. · Cochrane Database Syst Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- CYP3A4*22 Genotype-Guided Dosing of Kinase Inhibitors in Cancer Patients.
van Eerden RAG, IJzerman NS, van Meekeren M, et al. · Clin Pharmacokinet 2023 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Recent advances in the molecular targeted drugs for prostate cancer.
Gao P, Li T, Zhang K, et al. · Int Urol Nephrol 2023 · Systematic Review
- Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Ghatalia P, Morgan CJ, Choueiri TK, et al. · Crit Rev Oncol Hematol 2015 · Meta-Analysis, Review
- Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms.
Grillo F, Florio T, Ferraù F, et al. · Endocr Relat Cancer 2018 · Systematic Review
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.